EMEA PHARMACEUTICAL NEWS IN BRIEFS
October 1st, 2009
BY KEITH NUTHALL
THE EUROPEAN Medicines Agency (EMEA) has released another priority for drug safety research in 2010 - studies into the long-term adverse skeletal effects of bisphosphonates - http://www.emea.europa.eu/pdfs/human/phv/49371109en.pdf. It has also released an opinion on bisphosphonates and osteonecrosis of the jaw -http://www.emea.europa.eu/pdfs/human/opiniongen/29112509en.pdf
*EMEA has also released more information on the payment of fees for its services
- http://www.emea.europa.eu/pdfs/general/admin/fees/implementing_rules.pdf and ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.